Cargando…

Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation

Severe acute respiratory syndrome coronavirus 2 cell entry depends on angiotensin-converting enzyme 2 and transmembrane serine protease 2 and is blocked in cell culture by camostat mesylate, a clinically proven protease inhibitor. Whether camostat mesylate is able to lower disease burden in coronavi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hofmann-Winkler, Heike, Moerer, Onnen, Alt-Epping, Sabine, Bräuer, Anselm, Büttner, Benedikt, Müller, Martin, Fricke, Torben, Grundmann, Julian, Harnisch, Lars-Olav, Heise, Daniel, Kernchen, Andrea, Pressler, Meike, Stephani, Caspar, Tampe, Björn, Kaul, Artur, Gärtner, Sabine, Kramer, Stefanie, Pöhlmann, Stefan, Winkler, Martin Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671878/ https://www.ncbi.nlm.nih.gov/pubmed/33225308 http://dx.doi.org/10.1097/CCE.0000000000000284

Ejemplares similares

Fatal septic shock due to Capnocytophaga canimorsus bacteremia masquerading as COVID-19 pneumonia - a case report
por: Meyer, Eva Christina, et al.
Publicado: (2021)

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
por: Hoffmann, Markus, et al.
Publicado: (2020)

Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia
por: Sakr, Yasser, et al.
Publicado: (2021)

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
por: Hoffmann, Markus, et al.
Publicado: (2021)

Facial nerve neurographies in intensive care unit-acquired weakness
por: Lochter, Maximilian, et al.
Publicado: (2023)

Urinary Levels of SARS-CoV-2 Nucleocapsid Protein Associate With Risk of AKI and COVID-19 Severity: A Single-Center Observational Study
por: Tampe, Désirée, et al.
Publicado: (2021)

Activation of Sphingomyelinase-Ceramide-Pathway in COVID-19 Purposes Its Inhibition for Therapeutic Strategies
por: Abusukhun, Murad, et al.
Publicado: (2021)

Case Report: Interferon- γ Rescues Monocytic Human Leukocyte Antigen Receptor (mHLA-DR) Function in a COVID-19 Patient With ARDS and Superinfection With Multiple MDR 4MRGN Bacterial Strains
por: Grimm, Clemens, et al.
Publicado: (2021)

Erythrocytes increase endogenous sphingosine 1-phosphate levels as an adaptive response to SARS-CoV-2 infection
por: Winkler, Martin Sebastian, et al.
Publicado: (2021)

High class filtering facepiece (FFP) are fundamental and effective in protection of emergency health care workers: an observational cohort study in a German community
por: Lier, Martin, et al.
Publicado: (2021)

The Specific Bile Acid Profile of Shock: A Hypothesis Generating Appraisal of the Literature
por: Harnisch, Lars-Olav, et al.
Publicado: (2020)

Contraindications to the Initiation of Veno-Venous ECMO for Severe Acute Respiratory Failure in Adults: A Systematic Review and Practical Approach Based on the Current Literature
por: Harnisch, Lars-Olav, et al.
Publicado: (2021)

Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors
por: C, Amrutha M, et al.
Publicado: (2023)

Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial
por: Tobback, Els, et al.
Publicado: (2022)

Safety Evaluation and Population Pharmacokinetics of Camostat Mesylate and Its Major Metabolites Using a Phase I Study
por: Kim, Gwanyoung, et al.
Publicado: (2023)

Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions
por: Weiss, Johanna, et al.
Publicado: (2021)

Case Report: Interferon-γ Restores Monocytic Human Leukocyte Antigen Receptor (mHLA-DR) in Severe COVID-19 With Acquired Immunosuppression Syndrome
por: Dickel, Steffen, et al.
Publicado: (2021)

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19
por: Kosinsky, Yuri, et al.
Publicado: (2022)

Lung cell entry, cell–cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75
por: Arora, Prerna, et al.
Publicado: (2022)

Evidence that two instead of one defective interfering RNA in influenza A virus-derived defective interfering particles (DIPs) does not enhance antiviral activity
por: Bdeir, Najat, et al.
Publicado: (2021)

Development of immortalized rhesus macaque kidney cells supporting infection with a panel of viruses
por: Reiter, Stefanie, et al.
Publicado: (2023)

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
por: Karolyi, M., et al.
Publicado: (2022)

Camostat mesilate therapy for COVID-19
por: Uno, Yoshiharu
Publicado: (2020)

A Recombinant System and Reporter Viruses for Papiine Alphaherpesvirus 2
por: Rahman Siregar, Abdul, et al.
Publicado: (2022)

The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant
por: Arora, Prerna, et al.
Publicado: (2022)

A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19
por: Kitagawa, Junsaku, et al.
Publicado: (2021)

Longtime Neurologic Outcome of Extracorporeal Membrane Oxygenation and Non Extracorporeal Membrane Oxygenation Acute Respiratory Distress Syndrome Survivors
por: Harnisch, Lars-Olav, et al.
Publicado: (2019)

Virion Background and Efficiency of Virion Incorporation Determine Susceptibility of Simian Immunodeficiency Virus Env-Driven Viral Entry to Inhibition by IFITM Proteins
por: Wrensch, Florian, et al.
Publicado: (2017)

Rhesus macaque IFITM3 gene polymorphisms and SIV infection
por: Winkler, Michael, et al.
Publicado: (2017)

Quantification of urinary TIMP-2 and IGFBP-7: an adequate diagnostic test to predict acute kidney injury after cardiac surgery?
por: Wetz, Anna J, et al.
Publicado: (2015)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Predicting restoration of kidney function during CRRT-free intervals
por: Heise, Daniel, et al.
Publicado: (2012)

Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach
por: Sonawane, Kailas D., et al.
Publicado: (2021)

Biomarkers of Cholestasis and Liver Injury in the Early Phase of Acute Respiratory Distress Syndrome and Their Pathophysiological Value
por: Harnisch, Lars-Olav, et al.
Publicado: (2021)

Quantification of Bile Acids in Cerebrospinal Fluid: Results of an Observational Trial
por: Harnisch, Lars-Olav, et al.
Publicado: (2023)

Primate Simplexviruses Differ in Tropism for Macaque Cells
por: Hofmann-Winkler, Heike, et al.
Publicado: (2022)

A system for production of defective interfering particles in the absence of infectious influenza A virus
por: Bdeir, Najat, et al.
Publicado: (2019)

Analysis of IFITM-IFITM Interactions by a Flow Cytometry-Based FRET Assay
por: Winkler, Michael, et al.
Publicado: (2019)

Weaning beginnt bereits mit der Beatmung: Zentraler Bestandteil des intensivmedizinischen Alltags
por: Moerer, Onnen
Publicado: (2022)

A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19
por: Kim, Yeon-Sook, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_snoa4ruu28hknjfotgni8ouj0h